CKD-519
CAS No. 1402796-27-3
CKD-519 ( Rocacetrapib | CKD519 )
产品货号. M11682 CAS No. 1402796-27-3
CKD-519 (Rocacetrapib, CKD519) 是一种有效的选择性胆固醇酯转移蛋白 (CETP) 抑制剂,抑制人血清中 CETP 介导的胆固醇酯转移,IC50 为 2.3 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥3029 | 有现货 |
|
| 50MG | ¥17091 | 有现货 |
|
| 100MG | ¥25110 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CKD-519
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CKD-519 (Rocacetrapib, CKD519) 是一种有效的选择性胆固醇酯转移蛋白 (CETP) 抑制剂,抑制人血清中 CETP 介导的胆固醇酯转移,IC50 为 2.3 nM。
-
产品描述CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM; exhibites a maximum of 70%-86% inhibition of CETP activity and 25%-48% increase of HDL-C levels after two weeks of oral administration of 1, 3, or 10 mg/kg in transgenic mice expressing human CETP/apolipoprotein AI; CKD-519 (Rocacetrapib, CKD519) is being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol.Dyslipidemia Phase 2 Clinical.
-
体外实验——
-
体内实验——
-
同义词Rocacetrapib | CKD519
-
通路Metabolic Enzyme/Protease
-
靶点CETP
-
受体CETP
-
研究领域Cardiovascular Disease
-
适应症Dyslipidemia
化学信息
-
CAS Number1402796-27-3
-
分子量601.606
-
分子式C31H34F7NO3
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 66.67 mg/mL (110.82 mM)
-
SMILESC[C@H]1[C@@H](C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)OC(N1CC3=C(CCC(C)(C)C3)C4=C(OC)C=C(F)C(C(C)C)=C4)=O
-
化学全称(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5,5-dimethylcyclohex-1-en-1-yl}methyl)-4-methyl-1,3-oxazolidin-2-one
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kim CO, et al. Drug Des Devel Ther. 2016 Nov 15;10:3763-3770. eCollection 2016.
2. Lee S. Abstract 11228: a novel and potent CETP inhibitor, CKD-519 exerts strong HDL increment and anti-atherosclerotic effects. Circulation. 2013;128(Suppl 22):A11228.
021-51111890
购物车()
sales@molnova.cn

